Cargando…

A Case of Binocular Metastatic Choroidal Tumor Originating from Pulmonary Adenocarcinoma Successfully Treated with Molecular Target Therapy

The occurrence of ocular metastasis from lung cancer is uncommon. In our current case, we report on a 64-year-old male patient found to have metastatic lesions in both choroids after being diagnosed with lung adenocarcinoma. As the patient was found to have a mutation in the epidermal growth factor...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamaoka, Masataka, Igarashi, Tsutomu, Shiratori, Naka, Miyadera, Keiki, Sugano, Teppei, Noro, Rintaro, Takahashi, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601831/
https://www.ncbi.nlm.nih.gov/pubmed/37901630
http://dx.doi.org/10.1159/000530130
_version_ 1785126272802750464
author Yamaoka, Masataka
Igarashi, Tsutomu
Shiratori, Naka
Miyadera, Keiki
Sugano, Teppei
Noro, Rintaro
Takahashi, Hiroshi
author_facet Yamaoka, Masataka
Igarashi, Tsutomu
Shiratori, Naka
Miyadera, Keiki
Sugano, Teppei
Noro, Rintaro
Takahashi, Hiroshi
author_sort Yamaoka, Masataka
collection PubMed
description The occurrence of ocular metastasis from lung cancer is uncommon. In our current case, we report on a 64-year-old male patient found to have metastatic lesions in both choroids after being diagnosed with lung adenocarcinoma. As the patient was found to have a mutation in the epidermal growth factor receptor (EGFR), he was treated with the EGFR tyrosine kinase inhibitor (EGFR TKI), afatinib. However, the treatment response suggested the presence of a progressive disease. Thus, due to cancerous meningitis, the patient’s treatment was changed from afatinib to erlotinib, in addition to adding bevacizumab. Although the general condition of the patient did not change, improvement was noted for the choroidal metastasis. Moreover, the drug change also resulted in an improvement of the visual power of both eyes. Therefore, the results for this patient suggest that systemic administration of erlotinib and bevacizumab may be an effective treatment that leads to morphological and functional improvement in choroidal metastasis cases.
format Online
Article
Text
id pubmed-10601831
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-106018312023-10-27 A Case of Binocular Metastatic Choroidal Tumor Originating from Pulmonary Adenocarcinoma Successfully Treated with Molecular Target Therapy Yamaoka, Masataka Igarashi, Tsutomu Shiratori, Naka Miyadera, Keiki Sugano, Teppei Noro, Rintaro Takahashi, Hiroshi Case Rep Ophthalmol Case Report The occurrence of ocular metastasis from lung cancer is uncommon. In our current case, we report on a 64-year-old male patient found to have metastatic lesions in both choroids after being diagnosed with lung adenocarcinoma. As the patient was found to have a mutation in the epidermal growth factor receptor (EGFR), he was treated with the EGFR tyrosine kinase inhibitor (EGFR TKI), afatinib. However, the treatment response suggested the presence of a progressive disease. Thus, due to cancerous meningitis, the patient’s treatment was changed from afatinib to erlotinib, in addition to adding bevacizumab. Although the general condition of the patient did not change, improvement was noted for the choroidal metastasis. Moreover, the drug change also resulted in an improvement of the visual power of both eyes. Therefore, the results for this patient suggest that systemic administration of erlotinib and bevacizumab may be an effective treatment that leads to morphological and functional improvement in choroidal metastasis cases. S. Karger AG 2023-09-08 /pmc/articles/PMC10601831/ /pubmed/37901630 http://dx.doi.org/10.1159/000530130 Text en © 2023 The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Report
Yamaoka, Masataka
Igarashi, Tsutomu
Shiratori, Naka
Miyadera, Keiki
Sugano, Teppei
Noro, Rintaro
Takahashi, Hiroshi
A Case of Binocular Metastatic Choroidal Tumor Originating from Pulmonary Adenocarcinoma Successfully Treated with Molecular Target Therapy
title A Case of Binocular Metastatic Choroidal Tumor Originating from Pulmonary Adenocarcinoma Successfully Treated with Molecular Target Therapy
title_full A Case of Binocular Metastatic Choroidal Tumor Originating from Pulmonary Adenocarcinoma Successfully Treated with Molecular Target Therapy
title_fullStr A Case of Binocular Metastatic Choroidal Tumor Originating from Pulmonary Adenocarcinoma Successfully Treated with Molecular Target Therapy
title_full_unstemmed A Case of Binocular Metastatic Choroidal Tumor Originating from Pulmonary Adenocarcinoma Successfully Treated with Molecular Target Therapy
title_short A Case of Binocular Metastatic Choroidal Tumor Originating from Pulmonary Adenocarcinoma Successfully Treated with Molecular Target Therapy
title_sort case of binocular metastatic choroidal tumor originating from pulmonary adenocarcinoma successfully treated with molecular target therapy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601831/
https://www.ncbi.nlm.nih.gov/pubmed/37901630
http://dx.doi.org/10.1159/000530130
work_keys_str_mv AT yamaokamasataka acaseofbinocularmetastaticchoroidaltumororiginatingfrompulmonaryadenocarcinomasuccessfullytreatedwithmoleculartargettherapy
AT igarashitsutomu acaseofbinocularmetastaticchoroidaltumororiginatingfrompulmonaryadenocarcinomasuccessfullytreatedwithmoleculartargettherapy
AT shiratorinaka acaseofbinocularmetastaticchoroidaltumororiginatingfrompulmonaryadenocarcinomasuccessfullytreatedwithmoleculartargettherapy
AT miyaderakeiki acaseofbinocularmetastaticchoroidaltumororiginatingfrompulmonaryadenocarcinomasuccessfullytreatedwithmoleculartargettherapy
AT suganoteppei acaseofbinocularmetastaticchoroidaltumororiginatingfrompulmonaryadenocarcinomasuccessfullytreatedwithmoleculartargettherapy
AT nororintaro acaseofbinocularmetastaticchoroidaltumororiginatingfrompulmonaryadenocarcinomasuccessfullytreatedwithmoleculartargettherapy
AT takahashihiroshi acaseofbinocularmetastaticchoroidaltumororiginatingfrompulmonaryadenocarcinomasuccessfullytreatedwithmoleculartargettherapy
AT yamaokamasataka caseofbinocularmetastaticchoroidaltumororiginatingfrompulmonaryadenocarcinomasuccessfullytreatedwithmoleculartargettherapy
AT igarashitsutomu caseofbinocularmetastaticchoroidaltumororiginatingfrompulmonaryadenocarcinomasuccessfullytreatedwithmoleculartargettherapy
AT shiratorinaka caseofbinocularmetastaticchoroidaltumororiginatingfrompulmonaryadenocarcinomasuccessfullytreatedwithmoleculartargettherapy
AT miyaderakeiki caseofbinocularmetastaticchoroidaltumororiginatingfrompulmonaryadenocarcinomasuccessfullytreatedwithmoleculartargettherapy
AT suganoteppei caseofbinocularmetastaticchoroidaltumororiginatingfrompulmonaryadenocarcinomasuccessfullytreatedwithmoleculartargettherapy
AT nororintaro caseofbinocularmetastaticchoroidaltumororiginatingfrompulmonaryadenocarcinomasuccessfullytreatedwithmoleculartargettherapy
AT takahashihiroshi caseofbinocularmetastaticchoroidaltumororiginatingfrompulmonaryadenocarcinomasuccessfullytreatedwithmoleculartargettherapy